As part of our year in review, we’re sharing some results from studies that have been done. Glu was used to query patients about injectable glucagon, as part of a study sponsored by an emerging biotech partner interested in improving usability of injectable glucagon through alternative modes of administration. In only ten days data were collected from 126 respondents. Findings were shared with the United States Food and Drug Administration (FDA) to illustrate the shortcomings in current modes of glucagon administration.
The move corrects a strange regulatory gap in Medicare coverage.
Medicare Will Allow Dexcom G5 CGM to Be Used with Smart, Mobile Devices